

Azathioprine is an immunosuppressive agent. Suppresses tissue incompatibility.
Prevention of graft rejection (as part of combination therapy). Rheumatoid arthritis of severe course, systemic lupus erythematosus, dermatomyositis, periarteritis nodosa, juvenile vulvaris, idiopathic thrombocytopenic purpura, acquired hemolytic anemia, pyoderma gangrenitis, chronic hepatitis
1 tablet contains 50 mg of azathioprine.
No customer reviews for the moment.
Set individually, taking into account the nosological form and severity of the disease, the dosage of simultaneously prescribed drugs, hematological tolerance.
To prevent graft rejection, it is prescribed in a loading dose of 5 mg / kg / day in 2–3 doses for 1–2 months; then switch to a maintenance dose of 1 to 4 mg / kg / day for several years. In other cases, the daily dose is 1-2.5 mg / kg. The treatment is long.
From the hemopoietic system: mielodepressiya (leukopenia, thrombocytopenia, anemia); possible development of secondary infections, megaloblastic erythropoiesis and macrocytosis; in rare cases, hemolytic anemia.
From the digestive system: nausea, vomiting, anorexia, cholestatic hepatitis are possible; in recipients of transplants, pancreatitis, erosive-ulcerative lesions and bleeding from the gastrointestinal tract, necrosis and intestinal perforation were noted.
Allergic reactions: skin rash, arthralgia, myalgia, drug fever are possible.
Other: in rare cases - acute renal failure, acute pulmonary diseases, meningeal reactions.
Pregnancy, hypersensitivity to azathioprine and / or mercaptopurine.
With simultaneous use with co-trimoxazole may increase the myelotoxic effect of azathioprine. Cases of the development of severe leukopenia with simultaneous use with ACE inhibitors are described.
Azathioprine is contraindicated for use in pregnancy. During the period of treatment, women of childbearing age should use reliable methods of contraception.
If necessary, use during lactation should stop breastfeeding.
ATexperimental studies The teratogenic, embryotoxic and carcinogenic effects of azathioprine have been established.
During the first 8 weeks of treatment, weekly monitoring of the peripheral blood pattern is shown, and subsequently, 1-2 times a month, as well as periodic monitoring of the activity of hepatic transaminases, alkaline phosphatase and bilirubin level.
For violations of the kidney and / or liver, as well as while taking allopurinol azathioprine should be used in lower doses.
Studies and clinical trials of Azathioprine (Click to expand)